Literature DB >> 26333934

Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities.

Haruka Itakura1, Achal S Achrol2, Lex A Mitchell3, Joshua J Loya2, Tiffany Liu1, Erick M Westbroek4, Abdullah H Feroze2, Scott Rodriguez2, Sebastian Echegaray5, Tej D Azad2, Kristen W Yeom3, Sandy Napel3, Daniel L Rubin6, Steven D Chang2, Griffith R Harsh2, Olivier Gevaert7.   

Abstract

Glioblastoma (GBM) is the most common and highly lethal primary malignant brain tumor in adults. There is a dire need for easily accessible, noninvasive biomarkers that can delineate underlying molecular activities and predict response to therapy. To this end, we sought to identify subtypes of GBM, differentiated solely by quantitative magnetic resonance (MR) imaging features, that could be used for better management of GBM patients. Quantitative image features capturing the shape, texture, and edge sharpness of each lesion were extracted from MR images of 121 single-institution patients with de novo, solitary, unilateral GBM. Three distinct phenotypic "clusters" emerged in the development cohort using consensus clustering with 10,000 iterations on these image features. These three clusters--pre-multifocal, spherical, and rim-enhancing, names reflecting their image features--were validated in an independent cohort consisting of 144 multi-institution patients with similar tumor characteristics from The Cancer Genome Atlas (TCGA). Each cluster mapped to a unique set of molecular signaling pathways using pathway activity estimates derived from the analysis of TCGA tumor copy number and gene expression data with the PARADIGM (Pathway Recognition Algorithm Using Data Integration on Genomic Models) algorithm. Distinct pathways, such as c-Kit and FOXA, were enriched in each cluster, indicating differential molecular activities as determined by the image features. Each cluster also demonstrated differential probabilities of survival, indicating prognostic importance. Our imaging method offers a noninvasive approach to stratify GBM patients and also provides unique sets of molecular signatures to inform targeted therapy and personalized treatment of GBM.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2015        PMID: 26333934      PMCID: PMC4666025          DOI: 10.1126/scitranslmed.aaa7582

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  39 in total

1.  Are clusters found in one dataset present in another dataset?

Authors:  Amy V Kapp; Robert Tibshirani
Journal:  Biostatistics       Date:  2006-04-12       Impact factor: 5.899

2.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Authors:  Daphne A Haas-Kogan; Michael D Prados; Tarik Tihan; David A Eberhard; Nannette Jelluma; Nils D Arvold; Rachel Baumber; Kathleen R Lamborn; Ami Kapadia; Mary Malec; Mitchel S Berger; David Stokoe
Journal:  J Natl Cancer Inst       Date:  2005-06-15       Impact factor: 13.506

3.  Patterns of care for adults with newly diagnosed malignant glioma.

Authors:  Susan M Chang; Ian F Parney; Wei Huang; Frederick A Anderson; Anthony L Asher; Mark Bernstein; Kevin O Lillehei; Henry Brem; Mitchel S Berger; Edward R Laws
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

Review 4.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

5.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.

Authors:  Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

6.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

Authors:  R A Berkman; M J Merrill; W C Reinhold; W T Monacci; A Saxena; W C Clark; J T Robertson; I U Ali; E H Oldfield
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

7.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

Review 9.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  109 in total

1.  Special Section Guest Editorial:Radiomics and Imaging Genomics: Quantitative Imaging for Precision Medicine.

Authors:  Sandy Napel; Maryellen Giger
Journal:  J Med Imaging (Bellingham)       Date:  2015-12-11

Review 2.  Enabling Technologies for Personalized and Precision Medicine.

Authors:  Dean Ho; Stephen R Quake; Edward R B McCabe; Wee Joo Chng; Edward K Chow; Xianting Ding; Bruce D Gelb; Geoffrey S Ginsburg; Jason Hassenstab; Chih-Ming Ho; William C Mobley; Garry P Nolan; Steven T Rosen; Patrick Tan; Yun Yen; Ali Zarrinpar
Journal:  Trends Biotechnol       Date:  2020-01-21       Impact factor: 19.536

3.  Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Authors:  Zev A Binder; Amy Haseley Thorne; Spyridon Bakas; E Paul Wileyto; Michel Bilello; Hamed Akbari; Saima Rathore; Sung Min Ha; Logan Zhang; Cole J Ferguson; Sonika Dahiya; Wenya Linda Bi; David A Reardon; Ahmed Idbaih; Joerg Felsberg; Bettina Hentschel; Michael Weller; Stephen J Bagley; Jennifer J D Morrissette; MacLean P Nasrallah; Jianhui Ma; Ciro Zanca; Andrew M Scott; Laura Orellana; Christos Davatzikos; Frank B Furnari; Donald M O'Rourke
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

4.  Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.

Authors:  Yikyung Kim; Hwan-Ho Cho; Sung Tae Kim; Hyunjin Park; Dohyun Nam; Doo-Sik Kong
Journal:  Neuroradiology       Date:  2018-09-19       Impact factor: 2.804

5.  Relationship between Glioblastoma Heterogeneity and Survival Time: An MR Imaging Texture Analysis.

Authors:  Y Liu; X Xu; L Yin; X Zhang; L Li; H Lu
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

6.  Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.

Authors:  Nicholas Czarnek; Kal Clark; Katherine B Peters; Maciej A Mazurowski
Journal:  J Neurooncol       Date:  2017-01-10       Impact factor: 4.130

7.  Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways.

Authors:  Jia Wu; Yi Cui; Xiaoli Sun; Guohong Cao; Bailiang Li; Debra M Ikeda; Allison W Kurian; Ruijiang Li
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

8.  Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.

Authors:  Peng Lin; Yu-Ting Peng; Rui-Zhi Gao; Yan Wei; Xiao-Jiao Li; Su-Ning Huang; Ye-Ying Fang; Zhu-Xin Wei; Zhi-Guang Huang; Hong Yang; Gang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-17       Impact factor: 4.553

9.  Multi-Channel 3D Deep Feature Learning for Survival Time Prediction of Brain Tumor Patients Using Multi-Modal Neuroimages.

Authors:  Dong Nie; Junfeng Lu; Han Zhang; Ehsan Adeli; Jun Wang; Zhengda Yu; LuYan Liu; Qian Wang; Jinsong Wu; Dinggang Shen
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

10.  Radiomic features predict Ki-67 expression level and survival in lower grade gliomas.

Authors:  Yiming Li; Zenghui Qian; Kaibin Xu; Kai Wang; Xing Fan; Shaowu Li; Xing Liu; Yinyan Wang; Tao Jiang
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.